This refresh
Data-driven refresh July 7, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,233 tickers); 1,779 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90
Health Information Services · price $22.74 · 1Y $24.37 · 5Y $35.68 · 10Y $52.93
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 23.2x B+ · PEG 0.59 A-
Why now. Doximity's highly profitable digital platform for medical professionals is a compounding machine, evidenced by its exceptional 30.4% profit margin and robust $326m in free cash flow. With a compelling 0.59 PEG ratio, the market undervalues its ability to monetize essential workflow tools like Ask and Scribe, alongside sponsored content, within a sticky professional network. The crux is the persistent growth in engagement and monetization within its specialized healthcare ecosystem.
Moat. Doximity's moat is built on a powerful network effect among medical professionals in the US, amplified by its HIPAA-compliant workflow tools like Ask and Scribe, which embed the platform deeply into clinical practice. This specialized ecosystem, offering personalized newsfeeds and critical professional content, creates high switching costs and pricing power from its category leadership, driving its impressive 20.6% ROE. Competitors struggle to replicate this trusted, integrated professional network and its specialized data.
Risk. The bear case argues Doximity's growth trajectory is decelerating, with 13.1% revenue growth potentially insufficient to justify its 6.4 P/S multiple, especially given its high 1.29 beta. Skeptics point to increased competition for sponsored content from pharmaceutical manufacturers and health systems, or alternative professional networking tools, which could pressure its industry-leading profit margins. A sustained decline in member engagement or a significant contraction of its 30.4% profit margin would confirm the bear thesis.
Horizon. 1-3 yr $24.37 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.68 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $52.93 if current growth sustains into durable earnings power.
2. LRN — Stride, Inc. · score 89.3
Education & Training Services · price $91.07 · 1Y $104.73 · 5Y $153.34 · 10Y $227.46
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 14.3x A- · PEG 0.51 A-
Why now. Stride’s integrated virtual‑school platform is the engine of a secular shift toward blended public‑school learning, delivering compounding top‑line growth. The business is expanding revenue at 17.9% YoY while trading at a modest PE 14.3x and a sub‑1 PEG 0.51, and it generates $414m of free cash flow on a $3.9 b market cap – a rare cash‑rich growth story that will keep the compounding cycle alive.
Moat. The company’s end‑to‑end suite of online curriculum, enrollment software and progress‑tracking tools locks districts into a high‑switching‑cost ecosystem; schools that adopt the platform must re‑train staff and migrate data, creating a durable moat. This stickiness fuels the ROE 18.8%, reflecting pricing power as the preferred vendor for blended‑learning districts that cannot easily replace the integrated stack.
Risk. The stock has slumped from a 52‑week high of $171.17 to $91.07, a 47% decline that signals market scepticism that the current 12.2% profit margin can be sustained amid intensifying ed‑tech competition and potential budget cuts in public‑school funding. A further slowdown in the 17.9% revenue growth rate or a margin contraction would likely push the price back toward the lower half of its range, confirming the bear case.
Horizon. 1-3 yr $104.73 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $153.34 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $227.46 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89.2
Software - Application · price $281.17 · 1Y $486.61 · 5Y $712.45 · 10Y $1,057
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 17.2x A- · PEG 0.71 A-
Why now. Intuit's robust growth in its Global Business Solutions segment, driven by essential QuickBooks services and Mailchimp, is significantly undervalued, as evidenced by a PEG ratio of 0.71 and a P/E of 17.2. This combination of strong profitability (21.9% profit margin) and double-digit revenue expansion (15.6% FY YoY) positions INTU as a compelling compounder. The crux is the persistent demand for integrated financial and marketing solutions among small and mid-market businesses, which Intuit dominates.
Moat. Intuit's 22.2% ROE stems from the high switching costs inherent in its QuickBooks financial management and payroll solutions, which become deeply integrated into small and mid-market business operations. The comprehensive suite of services, including merchant payment processing and Mailchimp's marketing automation, creates a sticky ecosystem that is difficult for competitors to dislodge. This ecosystem provides significant pricing power and recurring revenue streams that fuel its sustained profitability.
Risk. Despite its strong market position, Intuit faces significant execution risk in maintaining growth across its diverse segments, particularly if competition intensifies in areas like financial management for small businesses or marketing automation. The stock's dramatic fall from its 52-week high of $813.70 to the current $281.17 indicates that market sentiment can turn sharply, suggesting investors are wary of potential deceleration or competitive pressures. A sustained slowdown in revenue growth below the current 15.6% FY YoY would confirm the bear case, signaling a loss of momentum in its core offerings.
Horizon. 1-3 yr $486.61 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $712.45 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $1,057 if current growth sustains into durable earnings power.
4. ADBE — Adobe Inc. · score 89
Software - Application · price $221.54 · 1Y $280.66 · 5Y $354.32 · 10Y $454.41
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 12.7x A · PEG 0.60 A-
Why now. Software - Application · market cap $88.1b. Down 43% from 52-week high of $386.60 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. PEG 0.60 — paying under fair value for the growth rate. 33 sell-side analysts rate this a Hold with a mean 1-yr target of $280.66 (implying +27% upside).
Moat. Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 63% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 142% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 43% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.43 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $280.66 (analyst consensus (n=33)) — multiple re-rating thesis requires a catalyst. 5 yr $354.32 at ~10% CAGR — dividend + buyback compounding. 10 yr $454.41 if the moat survives secular pressure.
5. PCTY — Paylocity Holding Corporation · score 88
Software - Application · price $118.84 · 1Y $152.58 · 5Y $223.39 · 10Y $331.39
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 25.4x B+ · PEG 0.91 B+
Why now. Paylocity presents a compelling growth opportunity, leveraging its integrated cloud-based human capital management and payroll software to capture market share. With a robust 14.8% FY YoY revenue growth and an impressive $487m in TTM free cash flow, the company is efficiently expanding its footprint. The 0.91 PEG ratio signals that this growth is currently undervalued, suggesting a strong runway for compounding returns as its comprehensive suite of payroll, HR, time & labor, and talent solutions continues to penetrate and retain its workforce clients.
Moat. Paylocity's durable edge stems from the high switching costs inherent in its comprehensive, integrated cloud-based human capital management and payroll software solutions. Once clients adopt its mission-critical payroll and tax services, HR solutions, and talent management platforms, the operational disruption and data migration required to switch providers are substantial. This stickiness underpins Paylocity's strong pricing power and recurring revenue, directly contributing to its impressive 21.9% Return on Equity.
Risk. Skeptics might argue that Paylocity's growth trajectory, while solid, faces increasing pressure from a highly competitive human capital management and payroll software market. Despite its comprehensive suite, specialized competitors could erode market share in specific segments like talent solutions or spend management, potentially decelerating the current 14.8% revenue growth. A sustained deceleration in revenue growth, coupled with a contraction in its 16.1% profit margin, would confirm that competitive intensity is eroding Paylocity's market position and pricing power.
Horizon. 1-3 yr $152.58 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $223.39 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $331.39 if current growth sustains into durable earnings power.
6. NBIX — Neurocrine Biosciences, Inc. · score 87.4
Drug Manufacturers - Specialty & Generic · price $177.49 · 1Y $195.99 · 5Y $286.95 · 10Y $425.66
FCF $831m C+ · Rev +21.4% A- · D/E 0.14 B+ · P/E 27.3x B · PEG 0.49 A
Why now. Neurocrine Biosciences is a high-quality compounder, leveraging its established portfolio of commercialized pharmaceuticals like INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia to fund robust pipeline development. The company's impressive 21.4% FY YoY revenue growth, coupled with a highly attractive 0.49 PEG ratio, signals significant undervaluation for a business generating $831m in TTM free cash flow. This cash-generative engine, fueled by successful product launches and a diverse therapeutic focus across neurological, psychiatric, endocrine, and immunological disorders, ensures sustained investment into future growth drivers.
Moat. Neurocrine's durable edge stems from its deep expertise in developing specialized pharmaceuticals for complex neurological and psychiatric disorders, exemplified by the market leadership of INGREZZA in tardive dyskinesia. This focus on high-barrier-to-entry therapeutic areas, backed by robust intellectual property and a diversified pipeline including candidates like NBI-1076986 for movement disorders, allows for significant pricing power and contributes to a strong 21.6% profit margin. The company's R&D engine consistently delivers innovative solutions, creating switching costs for patients and prescribers within these specialized markets.
Risk. The primary bear case against Neurocrine Biosciences centers on the inherent execution risk of its clinical development pipeline and potential competition for its key commercialized products. While the current 27.3 P/E TTM is justified by growth, any significant clinical trial failure for candidates like NBI-1076986 or Osavampator, or increased competition for INGREZZA, could severely impact future revenue streams and growth trajectory. A sustained deceleration in overall revenue growth below the current 21.4% would confirm the bear thesis, indicating a struggle to bring new blockbusters to market or defend existing ones.
Horizon. 1-3 yr $195.99 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $286.95 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $425.66 if current growth sustains into durable earnings power.
7. ADMA — ADMA Biologics, Inc. · score 87.1
Biotechnology · price $9.21 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
FCF $108m C · Rev +19.6% B+ · D/E 1.11 C · P/E 13.5x A- · PEG 0.69 A-
Why now. ADMA Biologics is a high-quality compounder, poised for continued expansion within the specialty plasma-derived biologics market, specifically driven by demand for its BIVIGAM and ASCENIV IVIG products for primary humoral immunodeficiency. With revenue growth at 19.6% and an attractive P/E of 13.5, the company trades at a compelling 0.69 PEG ratio, signaling undervaluation relative to its growth trajectory. The crux lies in ADMA's ability to sustain this robust top-line expansion while maintaining its impressive profitability.
Moat. ADMA's durable edge stems from its vertically integrated 'ADMA BioManufacturing and Plasma Collection Centers' segments, which provide critical control over the supply chain for its specialized plasma-derived biologics. The high regulatory barriers and complex manufacturing processes for products like BIVIGAM and ASCENIV create significant hurdles for new entrants, protecting market share. This operational control and specialized expertise contribute directly to its exceptional 42.4% Return on Equity, reflecting strong pricing power and efficient capital deployment in a niche, high-demand therapeutic area.
Risk. The primary bear case against ADMA centers on its elevated debt-to-equity ratio of 1.11, which could become a burden if growth decelerates or if capital markets tighten, especially given the capital intensity of plasma collection and biomanufacturing. Furthermore, while specialized, the market for IVIG products could face increased competitive pressure or pricing erosion from new therapies or expanded capacity from larger players. A sustained increase in the debt-to-equity ratio or a significant contraction in its 32.4% profit margin would confirm the bear thesis.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
8. NVDA — NVIDIA Corporation · score 86.1
Semiconductors · price $196.93 · 1Y $301.62 · 5Y $441.60 · 10Y $655.09
FCF $119.1b A · Rev +65.5% A · D/E 0.07 A- · P/E 30.2x B · PEG 0.60 A-
Why now. NVIDIA's unparalleled dominance in data center accelerated computing and AI solutions makes it a premier growth compounder, evidenced by its staggering 65.5% FY YoY revenue growth and an exceptional 63% profit margin. With a PEG ratio of just 0.6, the market is underappreciating the sustained earnings power from its foundational role in the global AI buildout. The thesis rests entirely on the continued, insatiable demand for its AI infrastructure.
Moat. NVIDIA's durable edge stems from its deep intellectual property and ecosystem leadership in data center accelerated computing and AI solutions, making its platforms indispensable. The company's extraordinary 81.7% Return on Equity is a direct result of its pricing power derived from category leadership in high-performance GPUs for both data centers and professional visualization. This entrenched position, built over decades, creates significant switching costs and a formidable barrier to entry for competitors.
Risk. The bear case centers on NVIDIA's elevated valuation and its high reliance on the cyclical nature of data center capital expenditure, particularly in AI infrastructure. A P/S TTM of 18.8 suggests significant future growth is already priced in, leaving little room for error if the rapid expansion in data center spending slows. Furthermore, its high beta of 2.21 indicates extreme sensitivity to market corrections. A sustained deceleration in revenue growth for its Compute & Networking segment, or a significant contraction in its profit margin, would confirm the bear thesis.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $441.60 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $655.09 if current growth sustains into durable earnings power.
9. EXLS — ExlService Holdings, Inc. · score 85.6
Information Technology Services · price $27.84 · 1Y $41.75 · 5Y $61.13 · 10Y $90.68
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 17.7x A- · PEG 0.87 B+
Why now. EXLS is riding the AI‑powered automation wave in insurance claims and underwriting, where its proprietary analytics platform is locking in high‑margin contracts across North America and Europe. The business is growing revenue at 13.6% YoY, generates $297m of free cash flow, and delivers a stellar 32.3% ROE, proving the model compounds faster than peers. The thesis rests on the continued expansion of AI‑driven digital operations that keep the revenue engine humming and cash flow robust.
Moat. EXLS’s moat comes from its deep, industry‑specific data sets and AI analytics embedded in the insurance, healthcare and banking segments, creating switching costs that lock clients into long‑term service agreements. Its pricing power in these high‑touch digital operations fuels a ROE of 32.3%, a level unattainable for generic IT outsourcers lacking domain expertise. The combination of proprietary algorithms and entrenched client relationships makes replication by competitors a multi‑year effort.
Risk. The bear case hinges on the concentration of revenue in the insurance vertical, where a slowdown in underwriting activity or a loss of a marquee client could crush growth, especially as the market expects a premium for AI‑centric services reflected in a P/E of 17.7x. A dip in revenue growth below 10% YoY or a margin compression below 10% would signal that the AI advantage is eroding, and the debt‑to‑equity of 0.67 could limit flexibility to invest in new capabilities. A sustained decline in the insurance AI spend cadence would break the compounding engine.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $61.13 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $90.68 if current growth sustains into durable earnings power.
10. CPRX — Catalyst Pharmaceuticals, Inc. · score 84.7
Biotechnology · price $31.49 · 1Y $31.67 · 5Y $46.36 · 10Y $68.78
FCF $208m C · Rev +19.8% B+ · D/E 0.00 A · P/E 18.2x A- · PEG 0.92 B+
Why now. Catalyst Pharmaceuticals is a high-quality compounder, leveraging its portfolio of rare disease treatments like Firdapse for LEMS and Fycompa for seizures to drive exceptional profitability and growth. A robust 37.1% profit margin on 19.8% FY YoY revenue growth translates into substantial free cash flow of $208m, which, combined with a low 0.92 PEG ratio, indicates efficient growth at a reasonable price. The crux of the thesis rests on the continued expansion and market penetration of its specialized therapies within the rare disease segment, particularly with AGAMREE for Duchenne Muscular Dystrophy, ensuring sustained compounding.
Moat. Catalyst's durable edge stems from its focused portfolio of commercial-stage medicines addressing rare diseases, such as Firdapse for LEMS and AGAMREE for Duchenne Muscular Dystrophy, which benefit from specialized regulatory pathways and limited competition. The company's impressive 21.9% ROE is a direct result of pricing power and market exclusivity derived from its intellectual property and established distribution channels within these niche therapeutic areas. This focus on rare diseases creates high switching costs for patients and prescribers, protecting its revenue streams.
Risk. The primary bear case against Catalyst Pharmaceuticals centers on its concentration within specific rare disease markets, making it vulnerable to new competitive entrants or shifts in treatment paradigms for conditions like LEMS or focal onset seizures. While current revenue growth is strong, any deceleration from the 19.8% FY YoY revenue growth could quickly re-rate its 18.2 P/E TTM multiple, especially if new therapies emerge to challenge Firdapse or Fycompa. A concrete signal confirming the bear case would be a significant decline in market share for its flagship products or a failure to successfully integrate and grow newer assets like AGAMREE.
Horizon. 1-3 yr $31.67 (analyst consensus (n=3)) — fundamentals + valuation re-rating. 5 yr $46.36 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $68.78 if current growth sustains into durable earnings power.
11. IT — Gartner, Inc. · score 84.3
Information Technology Services · price $140.80 · 1Y $165.00 · 5Y $241.58 · 10Y $358.36
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 13.9x A- · PEG 0.55 A-
Why now. Gartner represents a high-quality compounder, with its subscription-driven Insights segment generating substantial free cash flow. A $1.3b TTM free cash flow against a $9.4b market cap indicates strong cash generation, while a PEG ratio of 0.55 suggests undervaluation relative to its growth prospects. This combination of mission-critical insights and efficient operations positions Gartner to continue compounding value for shareholders.
Moat. Gartner's durable edge stems from its Insights segment, which embeds itself into clients' "mission-critical priorities" through subscription services offering data, benchmarks, and expert access. This creates significant switching costs, as organizations rely on Gartner's unique network of business and technology experts to inform strategic decision-making. The proprietary nature of its published content and expert network makes it incredibly difficult for competitors to replicate quickly.
Risk. Skeptics point to Gartner's modest 3.7% FY YoY revenue growth, arguing that the market for business and technology insights may be maturing or facing increased competition. The significant drop from its $403.96 52-week high to the current $140.80 suggests market concerns about future growth trajectory or valuation. A sustained decline in the profitability of its core Insights segment, evidenced by further contraction in its 11.4% profit margin, would confirm the bear case.
Horizon. 1-3 yr $165.00 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $241.58 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $358.36 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 83.7
Information Technology Services · price $89.55 · 1Y $142.82 · 5Y $209.11 · 10Y $310.20
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 12.9x A · PEG 0.45 A
Why now. EPAM’s digital platform engineering and cloud services are positioned to capture the ongoing enterprise cloud migration, driving revenue growth of 15.4% YoY, while generating free cash flow of $544m on a $4.7b market cap (≈11.6% FCF yield) and trading at a PEG of 0.45, which together prove the stock is massively undervalued relative to its growth. The compounding engine is the high‑margin, repeatable engineering contracts that should sustain a 12‑13% CAGR for years to come.
Moat. EPAM’s moat stems from its end‑to‑end digital engineering platform that embeds custom code, cross‑platform migration, and smart automation into client core systems, creating high switching costs and deep data integration. Its low debt‑to‑equity of 0.08 and consistent ROE of 11.3% reflect pricing power in high‑value software development engagements that competitors cannot replicate quickly without similar talent and delivery frameworks.
Risk. The bear case hinges on a potential slowdown in enterprise cloud spend, which would erode the 15.4% revenue growth and compress the already modest 7% profit margin; the stock’s beta of 1.43 amplifies any downside, and a missed earnings beat could force the market to re‑price the PE of 12.9, triggering a sharp correction. A sustained drop in margin or growth below 10% would confirm the risk and break the bull thesis.
Horizon. 1-3 yr $142.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $209.11 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $310.20 if current growth sustains into durable earnings power.
13. DXCM — DexCom, Inc. · score 83.3
Medical Devices · price $73.57 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +15.6% B+ · D/E 0.47 B · P/E 31.6x C+ · PEG 1.33 B
Why now. DexCom is a high-quality compounder, expanding its continuous glucose monitoring (CGM) leadership beyond insulin-dependent diabetes into the massive metabolic health market with products like Stelo. This strategic expansion underpins its robust 15.6% revenue growth and impressive 19.3% profit margin, driving substantial free cash flow of $1.4b. The core thesis rests on the persistent demand for precise glucose management and DexCom's ability to capture a growing share of non-insulin users, sustaining its compounding trajectory.
Moat. DexCom's durable edge stems from its established leadership and continuous innovation in integrated continuous glucose monitoring (CGM) systems like the Dexcom G7 and G6. This creates significant switching costs for patients and deeply embeds its technology into the practices of endocrinologists and physicians, driving its exceptional 31.5% Return on Equity. The expansion into new customer segments with Stelo further solidifies its market position and intellectual property in a critical medical device category.
Risk. The bear case argues DexCom's valuation, marked by a P/E of 31.6 and PS of 5.9, is already pricing in aggressive growth from its expansion into broader metabolic health markets with products like Stelo. This premium is particularly vulnerable given its high 1.45 beta, exposing investors to significant volatility if market sentiment shifts. A concrete signal confirming the bear case would be a sustained deceleration in revenue growth below the current 15.6%, indicating slower-than-expected adoption in these new segments or intensifying competitive pressures.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
14. META — Meta Platforms, Inc. · score 83
Internet Content & Information · price $615.58 · 1Y $828.17 · 5Y $1,213 · 10Y $1,799
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 22.4x B · PEG 0.84 B+
Why now. Meta Platforms is a compelling growth compounder, leveraging its dominant Family of Apps (FoA) to drive robust financial performance. The company's impressive 22.2% FY YoY revenue growth, coupled with a healthy 32.8% profit margin and an attractive 0.84 PEG ratio, indicates strong operational efficiency and future earnings potential. The core thesis rests on the persistent monetization of its vast global user base across Facebook, Instagram, and Messenger, which continues to expand and deepen engagement.
Moat. Meta's durable moat stems from the powerful network effects embedded within its Family of Apps, specifically Facebook, Instagram, and Messenger, where user value increases with each additional participant. This creates significant switching costs for individuals and businesses, solidifying its category leadership in digital connection and sharing. The exceptional 29% Return on Equity (ROE) is a direct result of this entrenched user base and the resulting pricing power in its advertising ecosystem, making it incredibly difficult for competitors to replicate.
Risk. The primary bear case against Meta centers on the significant capital allocation towards the Reality Labs (RL) segment, which presents an uncertain return on investment and could dilute the strong profitability of the core Family of Apps. While the overall business maintains a healthy 0.36 debt-to-equity ratio, continued heavy investment in RL without a clear path to profitability could strain free cash flow, especially given the stock's relatively high 1.25 beta indicating higher volatility. A sustained deceleration in user engagement or advertising revenue within the FoA segment, coupled with escalating losses in RL, would confirm the bear thesis.
Horizon. 1-3 yr $828.17 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,213 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,799 if current growth sustains into durable earnings power.
15. CARG — CarGurus, Inc. · score 82.5
Auto & Truck Dealerships · price $34.92 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 18.4x B+ · PEG 1.10 B+
Why now. CarGurus is a high-quality compounder leveraging its dominant online automotive marketplace to connect a large audience of car shoppers with an extensive network of dealers. This platform model generates robust revenue growth of 13.7% year-over-year, translating into a healthy 15.9% profit margin and impressive $293m in free cash flow. The thesis rests on the persistent network effect of its marketplace, which continues to attract both buyers and sellers, fueling recurring dealer subscription fees and advertising revenue.
Moat. CarGurus' durable edge stems from the powerful network effect of its online automotive marketplace, which becomes increasingly valuable as more car shoppers and dealers join. This category leadership allows for significant pricing power on dealer subscription fees and advertising, evidenced by an exceptional 62.9% Return on Equity. The integrated suite of products, including Digital Deal and Dealership Mode, further embeds CarGurus into the dealer workflow, creating high switching costs for its extensive network of partners.
Risk. The bear case centers on the cyclical nature of auto sales and intensifying competition within the online automotive platform space, which could pressure CarGurus' ability to maintain its growth trajectory and pricing power. A relatively high beta of 1.18 indicates sensitivity to broader market downturns, which could exacerbate any slowdown in dealer subscription or advertising revenue. The concrete signal confirming the bear case would be a sustained deceleration in revenue growth below its current 13.7% or a significant contraction in its 15.9% profit margin, indicating a loss of market share or pricing power.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
16. VEEV — Veeva Systems Inc. · score 82.2
Health Information Services · price $192.30 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 34.0x C+ · PEG 0.87 B+
Why now. Veeva Systems is a high-quality compounder, benefiting from its deeply embedded cloud-based software solutions for the life sciences industry, which drives persistent revenue growth and exceptional profitability. With a compelling PEG ratio of 0.87, the market is underpricing its future growth relative to earnings, especially given a robust 28.4% profit margin and substantial $1.7 billion in free cash flow. The crux of the thesis rests on the continued expansion and adoption of its specialized platforms like Veeva Vault CRM Suite and Veeva OpenData, which are indispensable to pharmaceutical and biotechnology companies globally.
Moat. Veeva's durable edge stems from its highly specialized, mission-critical cloud-based software tailored exclusively for the life sciences industry, creating significant switching costs for its pharmaceutical and biotechnology clients. Solutions like Veeva Vault CRM Suite and Veeva PromoMats become deeply integrated into customer workflows, making migration to alternative systems costly and disruptive. Furthermore, the Veeva Data Cloud, including Veeva OpenData and Veeva Link, establishes a proprietary data ecosystem that becomes more valuable with each new client, reinforcing a powerful network effect that competitors struggle to replicate.
Risk. Despite its niche, Veeva's valuation remains stretched for a company whose growth, while healthy, is showing signs of moderation from prior peaks, leaving it vulnerable to market corrections. The P/S TTM of 9.4, while common for high-quality software, could compress if the 16.3% FY YoY revenue growth decelerates further, particularly if competition emerges in specific product lines like Veeva Commercial Cloud or Veeva Data Cloud. A sustained trend of declining revenue growth rates over several quarters would confirm the bear case, indicating market saturation or increased competitive pressure within its specialized life sciences segment.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
17. RMD — ResMed Inc. · score 82
Medical Instruments & Supplies · price $219.75 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
FCF $1.8b C+ · Rev +9.8% B · D/E 0.13 B+ · P/E 21.2x B+ · PEG 1.23 B
Why now. ResMed's exceptional free cash flow generation of $1.8b, representing a robust FCF yield against its $31.9b market cap, makes it a compelling compounder. This cash engine, fueled by a strong 27.4% profit margin and nearly 10% revenue growth, allows continuous investment in its Sleep and Breathing Health segment, particularly cloud-connected diagnostic devices like NightOwl. The crux is RMD's ability to consistently convert the growing global demand for respiratory disorder solutions into shareholder value through efficient operations and product innovation.
Moat. ResMed's durable edge stems from its established leadership in medical devices for respiratory disorders, specifically its comprehensive suite of sleep recorders like ApneaLink Air and the portable, cloud-connected NightOwl. This category leadership, combined with the inherent switching costs for patients and clinicians once integrated into their care pathways, drives an impressive 23.4% Return on Equity. The company's deep integration of cloud-based software applications with its hardware creates a sticky ecosystem that competitors struggle to replicate, reinforcing its market position.
Risk. The primary bear case against ResMed centers on its valuation, with a P/E of 21.2x for a company growing revenue at 9.8%, suggesting limited upside if growth decelerates faster than expected. Competition in the Medical Instruments & Supplies sector, particularly for sleep apnea diagnosis and treatment, could introduce pricing pressure or technologically superior alternatives that erode market share in its core Sleep and Breathing Health segment. A sustained decline in profit margin below 25% would confirm the bear case, indicating a loss of pricing power or increased operational costs.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
18. CVSA — Covista Inc. · score 81.2
Education & Training Services · price $135.55 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 19.7x B · PEG 0.88 B+
Why now. Covista Inc. is a compelling growth story in essential education, particularly its resilient healthcare segments. Free cash flow of $336m on a $4.6b market cap indicates a robust FCF yield, while a PEG ratio of 0.88 suggests Covista is undervalued relative to its growth profile. This robust financial position, coupled with a 12.9% FY YoY revenue growth, positions CVSA for continued compounding driven by persistent demand for skilled professionals in nursing, health professions, medical, and veterinary fields.
Moat. Covista's durable edge stems from its established, accredited university brands like Chamberlain University and American University of the Caribbean, which create significant barriers to entry in regulated healthcare education. The high switching costs for students, coupled with the essential nature of the degrees offered in its Medical and Veterinary segments, lock in demand. Its 17.2% ROE reflects efficient capital deployment within a regulated industry where brand reputation and accreditation are paramount.
Risk. The primary threat to Covista lies in potential regulatory shifts impacting federal student aid or accreditation standards, which could disproportionately affect its Walden segment or broader enrollment. While its P/E of 19.7 is reasonable for a growth stock, any deceleration from the current 12.9% revenue growth could quickly re-rate the multiple downwards. A sustained decline in enrollment figures across its key university brands, particularly in the high-margin healthcare programs, would confirm the bear case.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
19. QCOM — QUALCOMM Incorporated · score 79.9
Semiconductors · price $182.97 · 1Y $215.42 · 5Y $315.40 · 10Y $467.87
FCF $12.5b A- · Rev +13.7% B+ · D/E 0.56 C+ · P/E 19.7x B+ · PEG 0.56 A-
Why now. QUALCOMM is a compelling growth story, rapidly expanding its reach beyond mobile devices through its QCT segment's strong traction in automotive systems for connectivity and ADAS/AD, and the burgeoning IoT market. This diversification, alongside a robust 13.7% FY YoY revenue growth and an attractive PEG ratio of 0.56, positions the company for continued compounding. The crux of the thesis rests on QCOM's ability to sustain high-margin growth by embedding its foundational wireless technologies into these expanding, high-value end markets.
Moat. QCOM's durable edge is rooted in its extensive intellectual property portfolio, managed by the QTL segment, which grants licenses for foundational wireless technologies, creating significant barriers to entry and recurring revenue. The exceptional 36.4% ROE is directly attributable to this high-margin licensing model and the proprietary nature of its integrated circuits and system software within the QCT segment, enabling strong pricing power. The deep integration of its connectivity and computing technologies across diverse platforms, from mobile devices to advanced ADAS/AD automotive systems, further creates high switching costs for customers.
Risk. The primary bear case against QCOM centers on its QCT segment's continued, albeit diversifying, exposure to the cyclicality and potential pricing pressures within the mobile devices market. Despite diversification efforts, a significant portion of its revenue remains tied to this mature segment, which could face decelerating growth. The stock's high Beta of 1.64 indicates substantial volatility, making it susceptible to broader sector downturns. A sustained deceleration in revenue growth below the current 13.7% or a contraction in the impressive 22.3% profit margin would confirm that diversification efforts are insufficient to offset core market pressures.
Horizon. 1-3 yr $215.42 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $315.40 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $467.87 if current growth sustains into durable earnings power.
20. MELI — MercadoLibre, Inc. · score 79.8
Internet Retail · price $1813.61 · 1Y $2,209 · 5Y $3,234 · 10Y $4,797
FCF $11.8b A- · Rev +34.3% A · D/E 1.70 C+ · P/E 47.8x C · PEG 1.09 B+
Why now. Internet Retail · market cap $91.9b. Down 29% from 52-week high of $2548.50 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $2,209 (implying +22% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $91.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Trailing P/E 48x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. E-commerce competition — Amazon, Walmart, Shein, and Temu have each forced the rest of the category to compete on price, fulfillment speed, or assortment; sustaining margins requires one of those being structurally defended.
Horizon. 1-3 yr $2,209 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,234 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,797 if current growth sustains into durable earnings power.
21. PODD — Insulet Corporation · score 79.6
Medical Devices · price $161.55 · 1Y $240.25 · 5Y $351.75 · 10Y $521.80
FCF $416m C · Rev +30.7% A · D/E 0.78 C+ · P/E 37.7x C+ · PEG 1.45 B
Why now. Medical Devices · market cap $11.2b. Down 54% from 52-week high of $354.88 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 24 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $240.25 (implying +49% upside).
Moat. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 137% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 54% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 38x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $240.25 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $351.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $521.80 if current growth sustains into durable earnings power.
22. DECK — Deckers Outdoor Corporation · score 78.6
Footwear & Accessories · price $106.08 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.1x B+ · PEG 1.30 B
Why now. Footwear & Accessories · market cap $14.7b. 16% off the 52-week high of $126.50. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $126.86 (implying +20% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
23. NFLX — Netflix, Inc. · score 77.2
Entertainment · price $76.18 · 1Y $113.94 · 5Y $166.82 · 10Y $247.47
FCF $11.9b A- · Rev +15.9% B+ · D/E 0.54 B · P/E 24.6x B · PEG 1.53 C+
Why now. Entertainment · market cap $320.8b. Down 41% from 52-week high of $129.32 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 44 sell-side analysts rate this a Buy with a mean 1-yr target of $113.94 (implying +50% upside).
Moat. Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $320.8b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.52 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $113.94 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $166.82 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $247.47 if current growth sustains into durable earnings power.
24. FISV — Fiserv, Inc. · score 75.7
Sector n/a · price $52.71 · 1Y $70.00 · 5Y $88.37 · 10Y $113.34
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.9x A- · PEG 2.48 C
Why now. Sector n/a · market cap $28.1b. Down 70% from 52-week high of $173.50 — deep drawdown territory. 26 sell-side analysts rate this a Hold with a mean 1-yr target of $70.00 (implying +33% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 70% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — multiple re-rating thesis requires a catalyst. 5 yr $88.37 at ~11% CAGR — dividend + buyback compounding. 10 yr $113.34 if the moat survives secular pressure.
25. YUMC — Yum China Holdings, Inc. · score 75.1
Restaurants · price $42.22 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +4.4% C+ · D/E 0.38 A- · P/E 16.2x B+ · PEG 1.04 B+
Why now. Restaurants · market cap $14.6b. Down 28% from 52-week high of $58.39 — deep drawdown territory. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $61.34 (implying +45% upside).
Moat. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 98% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
26. ULTA — Ulta Beauty, Inc. · score 74.8
Specialty Retail · price $453.78 · 1Y $627.25 · 5Y $918.36 · 10Y $1,362
FCF $1.1b C+ · Rev +9.7% B · D/E 0.89 B · P/E 17.0x B+ · PEG 1.60 C+
Why now. Specialty Retail · market cap $19.5b. Down 37% from 52-week high of $714.97 — deep drawdown territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $627.25 (implying +38% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $627.25 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $918.36 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,362 if current growth sustains into durable earnings power.
27. EME — EMCOR Group, Inc. · score 73.9
Engineering & Construction · price $768.38 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +16.6% B+ · D/E 0.13 A- · P/E 25.8x B+ · PEG 0.41 A
Why now. Engineering & Construction · market cap $34.2b. 19% off the 52-week high of $951.96. Revenue growing +17%, comfortably above the S&P median. PEG 0.41 — paying under fair value for the growth rate. 7 sell-side analysts publish a mean 1-yr target of $1,000 (implying +30% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
28. VST — Vistra Corp. · score 73.7
Utilities - Independent Power Producers · price $155.73 · 1Y $222.89 · 5Y $281.39 · 10Y $360.88
FCF $1.8b C+ · Rev +19.1% B+ · D/E 3.55 D · P/E 26.1x C · PEG 0.45 A
Why now. Utilities - Independent Power Producers · market cap $52.5b. Down 29% from 52-week high of $219.82 — deep drawdown territory. Revenue growing +19%, comfortably above the S&P median. PEG 0.45 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $222.89 (implying +43% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 40% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $52.5b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. D/E 3.55 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $222.89 (analyst consensus (n=18)) — multiple re-rating thesis requires a catalyst. 5 yr $281.39 at ~13% CAGR — dividend + buyback compounding. 10 yr $360.88 if the moat survives secular pressure.
29. SE — Sea Limited · score 73.2
Internet Retail · price $104.23 · 1Y $140.26 · 5Y $205.35 · 10Y $304.62
FCF $4.5b B · Rev +36.4% A · D/E 0.28 A- · P/E 41.0x C · PEG 1.48 B
Why now. Internet Retail · market cap $63.8b. Down 48% from 52-week high of $199.30 — deep drawdown territory. Revenue growing +36% — in hypergrowth territory. 28 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $140.26 (implying +35% upside).
Moat. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $63.8b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 48% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.55 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $140.26 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $205.35 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $304.62 if current growth sustains into durable earnings power.
30. APP — AppLovin Corporation · score 72.2
Advertising Agencies · price $527.98 · 1Y $654.47 · 5Y $958.20 · 10Y $1,421
FCF $4.4b B · Rev +70.0% A · D/E 1.63 C · P/E 46.0x C · PEG 1.45 B
Why now. Advertising Agencies · market cap $177.4b. Down 29% from 52-week high of $745.61 — deep drawdown territory. Revenue growing +70% — in hypergrowth territory. 30 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $654.47 (implying +24% upside).
Moat. Net margin 64% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 112% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $177.4b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Beta 2.48 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 46x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 28.8x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Horizon. 1-3 yr $654.47 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.20 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,421 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.